Civitas raises $38M to advance drug for Parkinson's complication

09/12/2013 | American City Business Journals

A Series B funding round has brought in $38 million for Chelsea, Mass.-based biotech firm Civitas Therapeutics. Civitas plans to use the money to support clinical development of its experimental drug CVT-301, which is under development for debilitating motor fluctuations in Parkinson's disease patients.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC